Wednesday, July 25, 2012 A new food product

Do you know someone with very mild or mild Alzheimer's disease symptoms? Here's a food product that that has worked to improve memory in this group. Offer this message to anyone you know in this category. The  problem is, of course, that most family members are so in denial of this dreaded disease that they don't or won't recognize mild symptoms as a disease and by the time they do, the food product made by Dannon which is owned by Nestle, will no longer be effective. That's what this blog is for. Be prepared better than I was when Alzheimer's disease descended upon my husband.
July 23, 2012 (Vancouver, British Columbia) — Administration of a medical food designed to improve synaptic dysfunction is associated with continuous memory improvement in patients with mild Alzheimer's disease (AD), new research shows.
Presented here at the Alzheimer's Association International Conference (AAIC) 2012, results from an open-label extension (OLE) trial of a medical nutrition product (Souvenaid, Nutricia/Danone) showed that memory performance continued to improve in drug-naïve patients with mild AD for up to 48 weeks.
These latest OLE results immediately follow those of the double-blind, randomized controlled Souvenir II study, published in the July issue of the Journal of Alzheimer's Disease, which showed significant improvement in memory performance compared with placebo over 24 weeks.
As presented by Philip Scheltens, MD, PhD, professor of cognitive neurology and director of the Alzheimer Center at the VU University Medical Center in Amsterdam, the Netherlands, the results from the 24-week OLE study "were exactly what we hoped for."

Dr. Philip Scheltens

At 48 weeks, memory of participants in the group randomly assigned to receive active treatment and who continued to receive Souvenaid in the OLE part of the study improved even further.
"There was no ceiling effect," he said.
Furthermore, study participants who were in the placebo group in the randomized controlled period of the trial and who were switched to the active treatment in the OLE study also experienced significant memory improvement.
"The bottom line is that we have now conducted 2 large studies with this medical food that aims to restore the function of synapses in mild to very mild Alzheimer's disease and have proven that it improves memory," Dr. Scheltens told Medscape Medical News.
He added that the findings also show that Souvenaid is "very safe and well tolerated" and confirm the results of the Souvenir I trial, the very first proof of concept study, which was published in the journal Alzheimer's & Dementia and reported byMedscape Medical News at that time